Northway Biotech
VILNIUS, LITHUANIA / ACCESSWIRE / November 16, 2023 / Northway Group is embarking on a project to establish Europe's largest biotechnology hub, BIO CITY, in Vilnius, the capital of Lithuania. It includes 6 large biotechnological complexes - 4 state-of-the-art GMP manufacturing plants and 2 advanced scientific research centres - that will be built in an area equivalent to 10 football fields. The total investment for this biotech campus is projected to reach approximately 7 billion euros over the next decade.
Northway Group is in the process of constructing Europe's largest biotechnology hub, with the inaugural Gene Therapy Center set to be operational in 2024.
"A science-based economy, supported by bright minds and intelligent entrepreneurs, is the foundation for Lithuania's long-term economic prosperity. In the past, our growth was constrained by a lack of fossil resources, but today, we are boldly moving forward, relying on modern technologies. The new biotechnology hub embodies the direction of Lithuania's innovative economy. It also promises new inventions that will enable people with serious illnesses to become full members of society, thereby reducing exclusion," says the President of the Republic of Lithuania, Gitanas Nausėda.
Prof. Vladas Algirdas Bumelis, founder and CEO of Northway Biotech and Celltechna, key components of the Northway Group, highlighted Lithuania's strong global standing in biotechnology. The aim of the BIO CITY project is to further solidify this position with four advanced biomanufacturing facilities and two innovative research centres, significantly boosting Lithuania's prominence in the international biotech sphere.
The Speaker of the Seimas, parliament of Lithuania, states that the new biotech city being developed in Vilnius will strengthen the competitiveness of our country. "Lithuanian life sciences industry has ambitions and potential to become a global leader in this field: a leader who will significantly contribute to the development of scientific research for the well-being of man, nature and planet, and will facilitate new opportunities to deal with global health, sustainable development and other challenges," says Viktorija Čmilytė-Nielsen.
Vision of BIO CITY: A European Biotechnology Leader
"We envision BIO CITY as a frontrunner in the European biotechnology, by uniquely integrating various biotech segments into a single, synergistic ecosystem. This multifunctional complex will catalyse interdisciplinary collaborations, the quick realisation of ideas and technological advancements. Our unique model, which brings together diverse biotechnology fields in one location, is set to revolutionise the European biotech landscape," said Prof. V. A. Bumelis.
Gene Therapy Centre will Open in 2024
The first facility to open its doors in the biotech hub BIO CITY will be the Gene Therapy Centre, which is currently under construction and is being built by Northway Group's subsidiary, Celltechna. This centre, the first and so far the only one of its kind in the Baltic States, will bolster Lithuania's role in gene therapy, addressing the needs of the 280 million individuals worldwide who are affected by genetic diseases.
"Our state-of-the-art facility will be instrumental in both research and production, offering new treatments for previously incurable diseases. This will not only augment our CDMO (Contract Development and Manufacturing Organisation) capabilities, but also position us for global competition and collaborations," added Prof. V. A. Bumelis.
The Gene Therapy Centre, which is expected to become operational in the second quarter of 2024, will specialise in gene therapy research and GMP manufacturing. Representing an investment of 50 million euros, the facility will span 8,000 square metres and is anticipated to create over 100 high-value jobs. The centre will work in synergy with Northway Biotech. Established in 2004, Northway Biotech is a leading provider of CDMO services in the field of biologics, with a focus on the development and manufacturing of recombinant proteins and antibodies.
A Comprehensive Lithuanian Biotech Hub
By 2030, BIO CITY will see the inauguration of five additional complexes, including centres for R&D and Virology, Life Sciences Industry Smart Services, Stem Cell Research and 3D Bioprinting, as well as two large-scale production centres for mammalian and microbial products. The entire BIO CITY complex will span an area equivalent to 10 football fields, with the total investment expected to reach around 7 billion euros over the next decade.
"We will not only focus on contract development and manufacturing services, but will also invest significantly in the operation of scientific research centres. Scientific activity enhances a country's competitiveness and generates value in various forms, beyond just the economic aspect. Modern biotechnologies, such as gene editing and cell therapies, are advancing rapidly. Lithuania can pride itself on having some of the most talented scientists and robust expertise in these areas. The development of the biotech campus in Vilnius means we are poised to foster new partnerships with innovative startups, research institutions and pharmaceutical companies on a global scale. We are actively seeking partnerships and offer a warm invitation to investors who are enthusiastic about joining this exciting venture," said Prof. V. A. Bumelis.
Upon its completion, BIO CITY is expected to offer employment to approximately 2,100 highly skilled professionals, including scientists, biotechnologists, and medical engineers.
Lithuania is Among the Leaders in the Global Biotechnology Market
The global biotechnology market, currently valued at over 1,130 billion euros, is anticipated to grow to be worth more than 2,775 billion euros by 2030. Lithuania holds a strong position in this market, ranking among the Top 35 innovative countries in the biotechnology field, according to Scientific American Worldview.
"Every year, Lithuania is mentioned in the field of Life Sciences more often, and the ambitious BIO CITY project will contribute to our leadership. Our vision is coming to life - we are talking about world-class Life Sciences infrastructure and a competitive sector capable of building innovative products. In 2022, companies in the sector posted combined revenues of 1.5 billion euros, while exporting their goods to more than 100 countries. Overall, Life Sciences is a leading sector in Lithuania, when it comes to creating and implementing innovative solutions," states Aušrinė Armonaitė, the Minister of the Economy and Innovation.
Over 80 life science companies operate in Lithuania, contributing about 2.5% to the country's GDP. The Northway group, a key player in Lithuania's biotech sector, manages seven companies: five in Lithuania and one each in the UK and the US, with the US entity being recognised as the largest biotech investor from the Baltic region in recent years. Employing more than 200 specialists, these companies provide services to a diverse array of international biopharmaceutical firms, ranging from small to large enterprises, predominantly operating in both Europe and the US.
BIO CITY Contacts:
Vladas Algirdas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Contact Information:
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Related Files
BIO CITY LOGO_ORANGE.png
BIO CITY LOGO_BLACK.png
Related Images
SOURCE: Northway Healthcare Group
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/804258/the-largest-biotech-city-in-europe-will-soon-be-built-with-an-investment-amounting-to-7-billion-euros
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Xsens Announces New Xsens Link for Motion Capture Across Humanoid Robotics, Health, Sports, and Entertainment12.11.2025 10:00:00 CET | Press release
Next-Generation motion capture from Xsens combines smarter sensors, seamless connectivity, and adaptive design to deliver precise, real-world motion data. ENSCHEDE, NL / ACCESS Newswire / November 12, 2025 / Xsens, a Movella brand and world leader in inertial motion capture technology, today announced the launch of the next-generation Xsens Link, an all-new motion capture system that redefines accuracy, usability, and versatility for users across industries. Redesigned from the ground up, the new Xsens Link delivers superior comfort, smarter data output, and minimal maintenance, empowering users to capture motion data with unprecedented speed and fidelity - whether in a robotics lab, film studio, or on the training field. "We've taken everything our customers love about Xsens and built the next generation around comfort, consistency, and flexibility," says Dennis Kloppenburg, product manager at Xsens. "From animators to athletes to robotics developers and researchers, The new Link deli
Air T Welcomes Creditor Support for Rex Acquisition11.11.2025 23:00:00 CET | Press release
MINNEAPOLIS, MINNESOTA / ACCESS Newswire / November 11, 2025 / Air T, Inc. (NASDAQ:AIRT) is pleased to announce that a majority of Rex's creditors-both in number and in value-have voted in favor of our bid to acquire Rex at the second meeting of creditors held on 11 November 2025. This strong endorsement reflects confidence in our vision for Rex and our commitment to regional aviation in Australia. We take our responsibilities under the proposed Deed of Company Arrangement seriously. We understand the Administrators intend to close the transaction by year-end, and we are working closely with all parties to ensure a smooth and timely completion. Air T is grateful for the support shown throughout this process and looks forward to finalizing the acquisition and beginning a new chapter for Rex and regional communities across Australia. NOTE REGARDING STAKEHOLDER QUESTIONS If you have questions related to this release or other Air T matters, please use our interactive Q&A capability, throug
MicroVision Announces Third Quarter 2025 Results11.11.2025 22:05:00 CET | Press release
REDMOND, WASHINGTON / ACCESS Newswire / November 11, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced its third quarter 2025 results. Key Business and Operational Highlights Appointed 30-year industry veteran Glen DeVos as Chief Executive Officer, elevating automotive capabilities. Introduced next generation solid-state lidar sensor, MOVIA S, offering an energy-efficient and cost-effective short-range solution for a wide variety of automotive, industrial, and defense sector applications. Launched industry-disrupting Tri-Lidar Architecture solution, offering an alternative to the lidar industry's myopic focus on single sensor solutions. Executed agreement to acquire Scantinel Photonics, a German developer of long-range FMCW lidar, joining investment and strategic partners in advancing lidar-on-chip solution for commercial vehicle and passenger car markets. Established design office and testing
Climate Goals Threatened by Industrialised Animal Farming, Reveals Key International Study11.11.2025 15:20:00 CET | Press release
LONDON, UK / ACCESS Newswire / November 11, 2025 / A new study in Animals highlights that industrialized animal farming is one of the most powerful - yet persistently neglected - forces driving the climate and biodiversity crises. The analysis, "The Missing Target: Why Industrialized Animal Farming Must Be at the Core of the Climate Agenda," synthesizes evidence from 47 international studies and concludes that reducing livestock production and embracing plant-based food systems is essential for meeting global climate goals. Major Insights Across global research, livestock farming contributes an estimated 12-20% of all greenhouse gas emissions annually, with the most comprehensive studies yielding the highest figures. The most modern accounting methods, which include the impacts of deforestation, bottom trawling and cooling effects from certain atmospheric pollutants, reveal that 52% of present-day global warming is attributable to animal agriculture. Animal agriculture occupies over 80
Resin Solutions Announces Commencement of up to $100 Million Global HTPB Production Expansion Initiative11.11.2025 15:00:00 CET | Press release
EXTON, PA / ACCESS Newswire / November 11, 2025 / Resin Solutions, Exton, PA, a portfolio company of Pacific Avenue Capital Partners, announced a multi-phase production capacity expansion initiative for its hydroxyl-terminated polybutadiene ("HTPB") product line, Poly bd®. Resin Solutions has begun the initial expansion phase, which includes debottlenecking initiatives and major capital investments at the company's Channelview, Texas and Ravenna, Italy facilities, which would expand existing capacity to meet expected additional demand for critical U.S. National Security Programs. In addition, the Resin Solutions Board has commenced a scoping and feasibility assessment to support additional greenfield capacity expansion in the United States and Europe. The Board of Resin Solutions, with support from Pacific Avenue Capital Partners, has authorized investment of up to $100 million to ensure Resin Solutions remains able to serve growing customer demand for HTPB in its aerospace, defense, a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom